Parliament has approved the importation of a vital medication required for children diagnosed with Attention Deficit Hyperactivity Disorder, marking a significant regulatory shift in the nation’s healthcare policy. The legislative action was initiated after the government submitted a motion seeking parliamentary approval to amend Schedule 1 of the nation’s Drugs Act, a mandate thoroughly reviewed by the Committee on National Security Services.
Prior to this milestone, Methylphenidate was strictly classified as a prohibited substance. A central nervous system stimulant used to treat ADHD and narcolepsy, the drug’s status was reconsidered by the executive branch, following guidance from the National Drug Control Council. The Cabinet determined it was necessary to seek parliamentary consent to amend the law, officially removing methylphenidate from the prohibited narcotics list.
Following a review of the submission by the government, members of the Committee on National Security Services voted unanimously in favour of authorising the medication. Attending members of Parliament subsequently passed the measure without dissent, legally sanctioning its importation into the country.
Methylphenidate is recognised as a primary, first-line clinical treatment for ADHD, one of the most prevalent developmental conditions in early childhood. Medical research demonstrates that integrating this medication with therapeutic interventions can substantially alleviate underlying symptoms. Relevant regulatory authorities affirmed the medication serves as an “essential and highly important treatment” for children managing the condition, reinforcing the clinical imperative of the legislative change.